Cambridge startup raises $110M for re-doseable gene therapies

One of Cambridge ’s emerging gene therapy startups has raised $110 million to support the company as it heads toward in-human trials.  Generation Bio closed the Series C round this week, bringing in new investors T. Rowe Price, Farallon and Wellington Management, as well as previous backers Atlas Venture, Fideli ty and others. The Series C round brings the total money raised by Generation Bio to more than $235 million. It’s also the first financing round led by former Vertex Pharmaceuticals…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news